Financials, Healthcare May 31, 2021 02:40 PM (GMT+8) · EqualOcean
Qichensheng has recently completed several hundred million yuan of pre-A + round financing. The current round of financing is led by the CICC Qide innovative biomedical equity investment fund of CICC capital, and the original shareholder sunshine capital continues to invest. The funds raised will be used to support the phase I clinical study of qichensheng's self-developed mRNA vaccine to be launched within this year. Founded at the end of 2015 and headquartered in Yizhuang, Beijing, Qichen is a biopharmaceutical company focusing on the technological innovation and R & D of mRNA, nucleic acid, cellular drugs and related industrial chain.
Related companies: